Pardes Biosciences, Inc. (PRDS)

NASDAQ: PRDS · IEX Real-Time Price · USD
14.48 0.53 (3.80%)
Jan 18, 2022 10:45 AM EST - Market open
Market Cap372.99M
Revenue (ttm)n/a
Net Income (ttm)-12.89M
Shares Out25.76M
EPS (ttm)-0.47
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close13.95
Day's Range13.86 - 14.48
52-Week Range9.69 - 17.76
Price Targetn/a
Earnings Daten/a

About PRDS

As of December 23, 2021, FS Development Corp. II was acquired by FS Development Corp. II, in a reverse merger transaction. FS Development Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.

IndustryShell Companies
Stock ExchangeNASDAQ
Ticker SymbolPRDS
Full Company Profile


Pardes Biosciences to Present at J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiv...

1 week ago - GlobeNewsWire

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and P...

Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19

3 weeks ago - GlobeNewsWire

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatmen...

SAN FRANCISCO & LARKSPUR, Calif.--(BUSINESS WIRE)--FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral.

4 weeks ago - Business Wire

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pard...

LARKSPUR, Calif.--(BUSINESS WIRE)--FS Development Corp. II announces effectiveness of registration statement for proposed business combination with Pardes

1 month ago - Business Wire

Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical C...

CARLSBAD, Calif. & LARKSPUR, Calif.--(BUSINESS WIRE)--Pardes Biosciences and FS Development Corp. II announce merger agreement creating publicly listed company advancing oral antiviral drugs.

6 months ago - Business Wire

2 New Healthcare SPACs Worth Adding to Your Watch List

SPAC-mania is in full swing, and the healthcare sector is starting to pop with new offerings.

Other symbols:GDRX
10 months ago - The Motley Fool

FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offe...

SAN FRANCISCO--(BUSINESS WIRE)-- #lifesciences--FS Development Corp. II announced today that it priced its initial public offering of 17,500,000 shares of Class A common stock at $10.00 per share.

11 months ago - Business Wire